Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 221Polycystic Ovary Syndrome 36Endometrial Neoplasms 15Ovarian Neoplasms 13Infertility 11Neoplasm Metastasis 9Carcinoma, Intraductal, Noninfiltrating 7Fallopian Tube Neoplasms 6Neoplasms 5Breast Diseases 5Triple Negative Breast Neoplasms 4Osteoporosis 4Leiomyoma 4Infertility, Female 4Breast Neoplasms, Male 4Breast Carcinoma In Situ 4Arthralgia 4Advanced Breast Cancer 4Recurrence 3Obesity 3Breast Cancer Metastatic 3Anovulation 3Uterine Neoplasms 2Solid Tumor 2Prostatic Neoplasms 2Progesterone Resistance 2Pancreatic Neoplasms 2Pain 2Leiomyosarcoma 2HR Positive HER2 Negative Advanced Breast Cancer 2

Interventions

Trastuzumab 2spartalizumab 1sintilimab 1pyrotinib 1pertuzumab 1palbociclib 1Taxes 1Letrozole 1Everolimus 1Capecitabine 1Albumin-Bound Paclitaxel 1Ado-Trastuzumab Emtansine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × HER2+ Breast Cancer × Letrozole × Clear all
NCT05429684 2022-06-23

Precise Therapy for Refractory HER2 Positive Advanced Breast Cancer

First Affiliated Hospital Xi'an Jiaotong University

Phase 3 Unknown
120 enrolled
Breast

HER2+ Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡